| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_716e9a2606ffd4ba1a2a3917e4a402fd |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-074 |
| filingDate |
2018-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8c9e6a301de0769f81307ae05917b4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe826b3e05a6f6786bf2cad39121c72b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9e77231fd00fd9459886d6fa408cfcc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f81470aa99323f2a6ebf6bd9a071b047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e8993d618f6e44f038d36da617c97ba |
| publicationDate |
2018-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2018230505-A1 |
| titleOfInvention |
Method for screening drugs for treatment of x-linked sideroblastic anemia |
| abstract |
The present invention relates to a method for screening drugs for the treatment of X-linked sideroblastic anemia that includes the following steps: (a) differentiating stem cells in which an X chromosome without an ALAS2 gene mutation from an X-linked sideroblastic anemia patient (XLSA) is deactivated and an X chromosome having an ALAS2 gene mutation is activated, into red blood cells in the presence and absence of a test substance, and measuring the differentiation efficiency; and (b) assessing that the test substance has the possibility of being a drug for the treatment of X-linked sideroblastic anemia when the differentiation efficiency in the presence of the test substance is higher than the differentiation efficiency in the absence of the test substance. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022145144-A1 |
| priorityDate |
2017-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |